1. Complete Response of Anaplastic Lymphoma Kinase–Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib 
Gita Thanarajasingam, MD, Eric S. Edell, MD, Svetomir M. Markovic, MD, PhD 
Mayo Clinic Proceedings 
Volume 91, Issue 9, Pages (September 2016)
DOI: /j.mayocp
Copyright © 2016 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure
Response to crizotinib in a patient with anaplastic lymphoma kinase–positive extranodal natural killer/T-cell lymphoma, nasal type, documented on positron emission tomography (PET) and bronchoschopy. A, PET before initiation of crizotinib, showing tumor-related plaquelike hypermetabolism of left main stem bronchus. B, Metabolic response of endobronchial tumor on PET after 6 weeks of crizotinib. C, Tumor occlusion of the left main stem bronchus before initiation of crizotinib. D, Bronchoscopic view of main carina; silicone stent in left main stem bronchus on day 7 of crizotinib. E, Bronchoscopic view of main carina; biopsy was negative for recurrent disease after 6 weeks of crizotinib therapy.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2016 Mayo Foundation for Medical Education and Research Terms and Conditions